Application of a clinical decision support tool for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicenter study

被引：0
|
作者：
Kim, K. [1 ]
Hong, S. W. [1 ]
Park, J. H. [1 ]
Hwang, S. W. [1 ,2 ]
Park, S. H. [1 ,2 ]
Yang, D. H. [1 ]
Byeon, J. S. [1 ]
Myung, S. J. [1 ]
Yang, S. K. [1 ,2 ]
Yoo, J. H. [3 ]
Boo, S. J. [4 ]
Kim, E. S. [5 ]
Lee, J. [6 ]
Kim, K. O. [7 ]
Ye, B. D. [1 ,2 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Inflammatory Bowel Dis, Seoul, South Korea
[3] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Sch Med, Seongnam, South Korea
[4] Jeju Natl Univ, Dept Internal Med, Sch Med, Jeju, South Korea
[5] Korea Univ, Anam Hosp, Dept Gastroenterol, Seoul, South Korea
[6] Chosun Univ, Dept Internal Med, Coll Med, Gwangju, South Korea
[7] Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P560
引用
收藏
页码：I503 / I504
页数：2
相关论文
共 50 条
  • [21] Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study
    Hajjat, Temara M.
    Mosha, Maua
    Whaley, Kaitlin G.
    Rosen, Michael J.
    Suppa, Carmine
    Markowitz, James
    Dufour, Lauren
    Sauer, Cary
    Shukla-Udawatta, Monica
    Boyle, Brendan
    Gibson, Meghan
    Shapiro, Jason
    Sams, Derica
    Sylvester, Francisco
    Hunter, Gabriele
    Perez, Maria E.
    Hyams, Jeffrey S.
    CROHNS & COLITIS 360, 2021, 3 (03)
  • [22] Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
    Amiot, Aurelien
    Grimaud, Jean-Charles
    Peyrin-Biroulet, Laurent
    Filippi, Jerome
    Pariente, Benjamin
    Roblin, Xavier
    Buisson, Anthony
    Stefanescu, Carmen
    Trang-Poisson, Caroline
    Altwegg, Romain
    Marteau, Philippe
    Vaysse, Thibaud
    Bourrier, Anne
    Nancey, Stephane
    Laharie, David
    Allez, Matthieu
    Savoye, Guillaume
    Moreau, Jacques
    Gagniere, Charlotte
    Vuitton, Lucine
    Viennot, Stephanie
    Aubourg, Alexandre
    Pelletier, Anne-Laure
    Bouguen, Guillaume
    Abitbol, Vered
    Bouhnik, Yoram
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (11) : 1593 - +
  • [23] Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
    Stallmach, A.
    Langbein, C.
    Atreya, R.
    Bruns, T.
    Dignass, A.
    Ende, K.
    Hampe, J.
    Hartmann, F.
    Neurath, M. F.
    Maul, J.
    Preiss, J. C.
    Schmelz, R.
    Siegmund, B.
    Schulze, H.
    Teich, N.
    von Arnim, U.
    Baumgart, D. C.
    Schmidt, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (11-12) : 1199 - 1212
  • [24] Role of vedolizumab trough levels in predicting clinical response in Inflammatory Bowel Disease: a multicentre prospective study
    Falzone, M. H.
    Ribaldone, D. G.
    Saracco, G. M.
    Bertani, L.
    Ceccarelli, L.
    Costa, F.
    Bottari, A.
    Fornaroli, G.
    Cusato, J.
    D'Avolio, A.
    Palermiti, A.
    Antonucci, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1216 - I1216
  • [25] Vedolizumab exposure in pregnancy: Outcomes from clinical studies in inflammatory bowel disease
    Dubinsky, M.
    Mahadevan, U.
    Vermeire, S.
    Abhyankar, B.
    Lasch, K.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S361 - S362
  • [26] Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease
    Mahadevan, U.
    Vermeire, S.
    Lasch, K.
    Abhyankar, B.
    Bhayat, F.
    Blake, A.
    Dubinsky, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (07) : 941 - 950
  • [27] Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study
    Ruth Garcia-Romero
    José Miguel Martinez de Zabarte Fernandez
    Gemma Pujol-Muncunill
    Ester Donat-Aliaga
    Oscar Segarra-Cantón
    Iñaki Irastorza-Terradillos
    Enrique Medina-Benitez
    Carlos José Ruiz-Hernández
    Marta Carrillo-Palau
    Ignacio Ros-Arnal
    Alejandro Rodriguez-Martínez
    Laura Escartin-Madurga
    Carolina Gutiérrez-Junquera
    Saioa Vicente-Santamaría
    Marta Velasco Rodriguez-Belvis
    Sonia Fernández-Fernández
    José Ramón Alberto-Alonso
    Montserrat Montraveta
    Ricardo Torres-Peral
    María Navalon-Rubio
    Víctor Manuel Navas-López
    Javier Martin de Carpi
    European Journal of Pediatrics, 2021, 180 : 3039 - 3040
  • [28] Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease
    Alric, Hadrien
    Amiot, Aurelien
    Kirchgesner, Julien
    Treton, Xavier
    Allez, Mathieu
    Bouhnik, Yoram
    Beaugerie, Laurent
    Carbonnel, Franck
    Meyer, Antoine
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (02) : 218 - 225
  • [29] Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study
    Cohen, Nathaniel Aviv
    Plevris, Nikolas
    Kopylov, Uri
    Grinman, Anna
    Ungar, Bella
    Yanai, Henit
    Leibovitzh, Haim
    Isakov, Naomi Fliss
    Hirsch, Ayal
    Ritter, Einat
    Ron, Yulia
    Shitrit, Ariella Bar-Gil
    Goldin, Eran
    Dotan, Iris
    Ben Horin, Shomron
    Lees, Charlie W.
    Maharshak, Nitsan
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (09) : 1076 - 1085
  • [30] Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study
    Lightner, Amy L.
    Mathis, Kellie L.
    Tse, Chung Sang
    Pemberton, John H.
    Shen, Bo
    Kochlar, Gursimran
    Singh, Amandeep
    Dulai, Parambir S.
    Eisenstein, Samuel
    Sandborn, William J.
    Parry, Lisa
    Stringfield, Sarah
    Hudesman, David
    Remzi, Feza
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (04) : 871 - 876
12345